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Take home message 
Disease management using a care bundle increases guideline adherence in 
general practice care for COPD  
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Abstract 
Background 
Disease management of chronic obstructive pulmonary disease (COPD) is complex 
and shortcomings in general practice care for COPD are common. A care bundle is a 
disease management aid reminding and steering specific elements of care. 
Objectives 
To test whether a COPD care bundle delivered to general practitioners (GPs) and 
practice assistants (PAs) increases the implementation of key elements of COPD 
care. 
Methods 
Cluster-randomised clinical trial, 1:1 randomisation of GPs, one-year follow-up. The 
intervention introduced a COPD care bundle and aimed at enhancing collaboration 
between GPs and PAs. The control group continued usual care. The primary 
outcome measure was the composite score from nine key elements of COPD care 
measured at patient level. 
Results 
We enrolled thirty-five GPs and 216 patients with a median age of 69 years, 59% 
female, 69% GOLD group A or B. After one year, the between-group difference in 
change of the primary outcome measure was +2.2 (95% CI +1.5 to +2.9) in favour of 
the intervention group. The intervention was associated with significantly higher 
implementation rates in 7 out of 9 key elements of care. 
Conclusion 
Disease management using a COPD care bundle increased the implementation of 
key elements of COPD care in general practice.  
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Introduction 
Chronic obstructive pulmonary disease (COPD) is of high and increasing 
prevalence and contributes importantly to worldwide years of life lost.[1, 2] COPD, 
however, is a preventable disease and modifiable risk factors and many effective 
interventions that reduce symptoms and improve prognosis have been identified. 
Guidelines amalgamate the existing evidence into practically applicable treatment 
recommendations.[3, 4] Nonetheless, we continue to observe shortcomings in COPD 
care delivered in general practice.[5–10] This is of special concern because the 
majority of COPD patients are treated in general practice and are in early disease 
stages when preventive interventions have the most potential to improve 
outcomes.[11–14] 
Evidence-based care for COPD is complex because it is stage- and symptom-
dependent and comprises multimodal interventions: Disease-assessment requires 
spirometry and collection of several variables (e.g. symptom severity and 
exacerbation history) to determine stage and treatment. Therapeutic measures with 
robust evidence-base (subsequently referred to as “key elements of COPD care”) 
comprise smoking cessation[15], influenza vaccination[16], appropriate 
pharmacologic therapy (also ensuring correct inhalation technique)[3, 17–21], 
pulmonary rehabilitation[22], sustaining physical activity[23], self-management 
education[24–26] and proactive, integrated disease management [27]. 
While some key elements of COPD care are straightforward to deliver such as 
influenza vaccination, others require time, knowledge, skills and inter-professional 
collaboration and coordination. The plethora of key elements and the individual 
implications of each one of them add up to a bundle of interventions that is complex 
to coordinate and deliver. This is critical, especially in general practice, where doctors 
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struggle with putting into practice the broad and continuously expanding field of 
general medicine and complex interventions are at risk of being left behind. 
Organisational changes and structured disease management aids can facilitate 
implementation of complex care pathways. For COPD, such approaches have 
already been successfully tested in hospital medicine. So called “COPD care 
bundles” have been used as reminder lists summarising key elements of care to be 
implemented on the individual patient-level before hospital discharge. In hospital-
based COPD care, care bundles succeeded in not only raising implementation rates 
of key elements of care but also in reducing readmission rates.[28] In primary care, 
COPD disease management trials are scarce. One trial aimed to increase 
implementation of best-practice guidelines by having home visits from specifically 
trained nurses who developed  individualised care plans with COPD patients and 
which resulted in improved quality of care.[29] A trial implementing a COPD 
management guideline, monthly nurse and three-monthly GP visits, a patient-specific 
care plan and enhancing collaboration between healthcare providers resulted in 
reduced hospital admissions, less hospital days and increased implementation of 
some key-elements of care.[30] Previous trials’ intensive and multimodal 
interventions, however, render attribution of the identified effects to individual 
intervention components difficult. 
The aim of this trial was to test, whether an intervention focussing on general 
practice teams including implementation of a COPD care bundle along with specific 
coaching to support organisational and behavioural changes would result in an 
increased implementation rate of key elements of COPD care. 
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Methods 
Study design, setting, registration and ethics statement 
We conducted a parallel group cluster randomised trial with general practices 
working in the Swiss canton of Zurich. The local ethics committee approved the study 
(ethics committee of the Canton of Zurich, reference number KEK-ZH 2013-0189), 
informed consent was retrieved from all participating subjects and the study was 
conducted according to tenets of the Declaration of Helsinki and good clinical 
practice guidelines. The trial has been registered at ClinicalTrials.gov 
(NCT01921556) and the trial’s study protocol is published.[31]  
 
Participants 
Recruitment of general practitioners (GPs) started in 2013 by mass mailings 
and visits at GP-network meetings. We enrolled 35 GPs after a nine months GP 
recruitment period. We trained GPs and their practice assistants in standardised 
spirometry to enhance accuracy of diagnostic testing for COPD. Patient recruitment 
started in December 2013. A detailed report of this trial’s recruitment period has been 
published.[12] 
Eligibility criteria for GPs were a) primary care physician in the canton of Zurich 
and b) board certification in general medicine or internal medicine. General 
practitioners approached consecutive patients aged at least 45 years, with at least 10 
pack-years (PY) smoking history and proposed to perform spirometry. If airflow 
obstruction (FEV1/FVC < 0.7) was confirmed, GPs gained informed consent if 
available and performed formal study inclusion. Exclusion criteria for patients were: 
emergency consultations, insufficient German language skills to complete study 
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questionnaires, asthma or hay fever or estimated life expectancy of less than six 
months. 
 
Data collection 
Data was collected using self-administered questionnaires (see supplementary 
material) at patient recruitment (T0) and 12 months after the intervention (T1). 
General practitioners completed a questionnaire about their own demographic 
characteristics and working environment. We pilot-tested the patient questionnaire 
with six COPD patients from the targeted group and made according adjustments to 
improve comprehensibility. The questionnaire asked for sociodemographic data, 
smoking status, 12-months retrospective view on delivered key elements of care (see 
below) and symptoms including the COPD assessment test (CAT). GPs filled in a 
questionnaire that asked for anthropometric patient data including current spirometry 
results, 12-months retrospective COPD exacerbations and COPD driven health 
service utilisation as well as prescribed pulmonary drugs. Table 1 shows the 
measured key elements of care including the levels of measurements and the 
applicable patient subgroups.   
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Table 1: List of measured key elements of COPD care including subgroup applicability, outcome 
component and measurement level 
 
Key elements of COPD care Applicable patient subgroup 
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1 Smoking cessation advice smokers only Primary Patient 
2 Smoking cessation intervention smokers only Primary Patient 
3 Influenza vaccination all patients Primary Patient 
4 Inhalation technique1) all patients Primary Patient 
5 Appropriate pharmacological treatment all patients Primary GP 
6 Assessment of physical activity all patients Primary Patient 
7 Advice for physical activity all patients Primary Patient 
8 Patient education all patients Primary Patient 
9 Assessment of exacerbation frequency all patients Primary GP 
10 Integration of other healthcare providers GOLD C and D patients Secondary Patient 
11 Referral to pulmonary rehabilitation GOLD C and D patients Secondary Patient 
12 Action plan for exacerbation management GOLD C and D patients Secondary Patient 
Table 1: Key elements of care including applicable patients and measurement level 
1) Performing: explanation and demonstration and assessment of patient’s inhaler technique 
2 
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Intervention 3 
We delivered the intervention after the patient recruitment period in a half-day 4 
workshop with GPs and their practice assistants. The intervention aimed at 5 
implementing the COPD care bundle and induce organisational and behavioural 6 
changes in the general practice teams: First, we refreshed knowledge about Swiss 7 
COPD guidelines[4] and distributed a pocket guide. Then, GPs and practice 8 
assistants were to discuss and tailor their individual pathways of COPD care. Case 9 
vignettes and role-plays were used to actively involve GPs and practice assistants 10 
with tasks and responsibilities. We proposed to use the COPD care bundle as a 11 
checklist to remind and tick-off the individual key elements of COPD care in individual 12 
patients. We expected the care bundle’s design as a checklist to increase internal 13 
motivation for behavior change.[32, 33] We delivered no intervention to the “usual 14 
care” control group. 15 
After 6 months, we delivered a three-hour refresher workshop to the practice 16 
teams again using case vignettes and role-plays after conducting a survey among 17 
practice teams to inform us about their specific needs for support. 18 
 19 
Outcomes 20 
Primary outcome 21 
Between-group difference in the change of implemented key elements of COPD 22 
care after one year (see Table 1; composite score being the sum of all implemented 23 
key elements ranging from 0 to 9 in smokers and 0 to 7 in non-smokers). 24 
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Secondary outcomes 25 
1. Between-group difference in proportions of GOLD C or D patients who 26 
received referral to pulmonary rehabilitation, a written action plan for 27 
exacerbation management or coordinated care. 28 
2. Between-group difference in symptom severity measured with the CAT 29 
instrument. 30 
 31 
Sample size 32 
Based on available data from Switzerland[5, 8], we assumed a mean number of 33 
4 (SD 2.3) implemented key elements of COPD care. We assumed a 1.5 points 34 
increase to be a relevant improvement and used this difference to calculate the 35 
sample size: Given a power of 90% and a significance level alpha of 5%, as well as 36 
an intra-cluster correlation coefficient of 0.04, we targeted at recruiting 30 GPs each 37 
recruiting eight patients, resulting in 240 patients. To allow for drop-out we set a 38 
recruitment target of 35 GPs. 39 
 40 
Randomisation 41 
The level of randomisation was the individual GP and allocation ratio was 1:1. 42 
We performed randomisation of GPs six months after initiation of patient recruitment 43 
to minimise the effect of the openly labelled treatment group allocation on recruitment 44 
performance. To balance groups for the considerable variation in recruiting 45 
performance, we ranked GPs according to their number of recruited patients and 46 
assigned random group allocation with block size of two. A researcher not involved in 47 
this study produced the random sequence using the statistic program STATA. This 48 
randomisation method was applied to minimise risk of imbalanced allocation counts 49 
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due to differences in recruiting performance. Furthermore, it balanced GPs for the 50 
possible confounding effect originating from the motivation to contribute to the trial, 51 
which we assumed to be associated with recruiting performance. The group 52 
allocations we communicated to GPs with the instruction not to pass this information 53 
to their patients. Patients, however, were aware that their GP would either continue 54 
usual care or start an experimental, potentially more comprehensive COPD care. 55 
 56 
Statistical methods 57 
 We report counts and proportions for categorical data as well as means and 58 
standard deviations (SD) or medians and interquartile ranges (IQR) as appropriate. 59 
For bivariate group comparisons, we used a Welch-test or a Wilcoxon rank sum test 60 
for continuous data and a Chi-squared for categorical data and report p-values. The 61 
primary outcome was calculated with a linear regression model.  The primary 62 
outcome measure at T1 was the dependent variable and, as independent variables, 63 
the group allocation as well as following adjustment variables to minimise 64 
confounding: count of implemented processes at T0, patient age, sex, education 65 
years, COPD stage and study follow-up time (days). We report the estimated 66 
between-group difference and the according 95% confidence intervals (95% CI). In a 67 
separate analysis we assess for a cluster-effect by adding the cluster variable 68 
(individual GPs) to the abovementioned regression model under a random effects 69 
assumption. We made no adjustments for a potential contamination effect originating 70 
from GPs in different study arms but located within the same group practice 71 
(therefore accepting a risk of underestimating the between group-difference in the 72 
trial results). To assess for selective dropout we analysed for between-group 73 
differences in counts and reasons for dropout. To assess the robustness of our 74 
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results we carried out sensitivity analyses simulating missing data under several 75 
assumptions (multiple imputation method, last observation carried forward and 76 
imputing the average score of the control group). Statistical analysis we performed 77 
using R version 3.2.0. (https://www.R-project.org/). 78 
  79 
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Results 80 
Study population 81 
Of the 35 GPs entering patient recruitment, 33 started recruiting and two 82 
withdrew before randomisation, therefore 33 GPs were randomized (16 intervention 83 
group and 17 control group). Eighteen GPs (contributing 111 patients) from 84 
intervention and control group were co-located in group practices. During the one-85 
year recruitment period, GPs recruited 216 patients (90% of recruitment goal) starting 86 
in December 2013. Recruitment stopped when the number of newly recruited 87 
patients per month was <5. The study intervention was delivered in January 2015 88 
and follow-up measures were conducted in January 2016. Patients median age was 89 
69 years, 59% were female, 69% GOLD group A or B. Per chance, the intervention 90 
group had less severe obstruction FEV1% (median= 70% v.s. 65%, p=0.035) and a 91 
lower CAT summary score (median = 9 v.s. 12, p=0.033). Table 2 and Table 3 give 92 
detailed patient and GP characteristics including study-group comparisons. 93 
At T1, 161 patients completed follow-up (drop-out rate 25%) and the study 94 
ended as set out in the protocol. Figure 1 depicts patient and cluster recruitment and 95 
retention over the trial periods. When testing dropout counts, a significant between-96 
group difference appeared (intervention group n=32, control group n=23, p=0.049). 97 
Active withdrawal of patients was the most common reason for discontinuation, there 98 
was however, no significant between-group difference in reasons for discontinuation 99 
(p=0.165).  100 
  101 
 14 
 
Table 2: Characteristics of total study patient population (n=216) and comparison by group assignment  
Category 
Intervention group Control group 
p value mean, median 
or n 
(SD), iqr or 
% 
mean, median 
or n 
(SD), iqr or 
% 
Total n 101 100% 115 100%   
Age (years) 68 63 to 75 67 60 to 73 0.260 
Male 60 59.4% 68 59.1% 0.967 
BMI 25.9 (5.99) 25.6 (4.63) 0.753 
GOLD group A1) 68 67.3% 59 51.3% 
0.101 
GOLD group B 9 8.9% 13 11.3% 
GOLD group C 16 15.8% 25 21.7% 
 GOLD group D 8 7.9% 18 15.7% 
FEV1 % 70 55 to 86 65 51 to 76 0.035 
≥1 exacerbations in past 12 months 27 26.7% 46 40.0% 0.089 
new COPD diagnosis at recruitment 37 36.6% 34 29.6% 0.270 
composite score of implemented 
key elements of care2) 4.1 (2.0) 4.6 (1.7) 0.035 
CAT summary score 9 6 to 15 12 8 to 16 0.033 
mMRC category 0 27 27.3% 25 22.7% 
0.904 
 mMRC category 1 42 42.4% 48 43.6% 
 mMRC category 2 23 23.2% 28 25.5% 
 mMRC category 3 7 7.1% 9 8.2% 
 mMRC category 4 0 0% 4 3.6% 
active smokers 56 55.4% 64 55.7% 0.976 
Pack-Years 44 30 to 59 45 35 to 60 0.277 
Diabetes 14 14.0% 14 12.6% 0.767 
Hypertension 50 51.0% 63 55.3% 0.537 
Coronary heart disease 16 16.3% 22 19.6% 0.533 
Congestive heart failure 12 12.0% 9 8.0% 0.335 
Depression 19 19.8% 23 20.5% 0.894 
Follow-up days 410 398 to 428 440.5 410 to 481 <0.001 
1) GOLD groups are classified according to the 2017 report[3] 
2) This T0 score comprises both patients with and without previously diagnosed COPD and is therefore not to be 
understood as a measure for usual care in general practice COPD care 
 
  102 
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Table 3: Characteristics of GPs randomised in the study (n=33) and comparison by group assignment  
Variable 
Intervention group Control group 
p value mean, 
median 
or n 
(SD), iqr or % 
mean, 
median 
or n 
(SD), iqr or % 
total n 16 100% 17 100%   
age (years) 50 44 to 59 47 42 to 56 0.407 
Sex (male) 13 81.2% 11 70.6% 0.438 
single practice 2 12.5% 2 11.8% 1.000 
group practice 14 87.5% 15 88.2% 1.000 
electronic medical record  13 81.2% 13 76.5% 1.000 
paper based medical record 3 18.8% 4 23.5% 1.000 
practice assistants workforce-
equivalents in full time jobs 2.3 1.9 to 3.4 2.7 1.8 to 4.0 0.773 
estimated number of patients seen 
per day 25 20 to 30 25 20 to 30 0.581 
patients approached 11 4 to 19 10 8 to 17 0.914 
patients recruited 6 2 to 10 6 5 to 10 0.638 
  103 
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Primary outcome 104 
After one year, the mean composite score of implemented key elements 105 
changed from 4.1 to 5.1 (+1.0) in the intervention group and changed from 4.6 to 3.5 106 
(-1.1) in the control group. A linear regression model adjusting for baseline 107 
characteristics (Table 4) revealed a between-group difference of +2.2 (95% CI +1.5 108 
to +2.9) implemented key elements in favour of the intervention group. Significantly 109 
increased implementation was found in 7 out of 9 individual key elements (Figure 2). 110 
We detected no significant cluster effect originating from individual GPs. 111 
 112 
Table 4: Coefficients of the primary outcome's linear regression model 
  Estimate 
Std. 
Error 
95% confidence 
interval 
intervention group (ref=control group) 2.2 0.64 1.5 to  2.9 
primary outcome at T0 0.4 0.38 0.2 to  0.6 
Age 0.0 0.11 -0.1 to  0 
sex (ref=female) 0.2 0.02 -0.5 to  0.9 
10 to 12 years education years (ref=<12) -0.5 0.36 -1.2 to  0.3 
>=13 years education years (ref=<12) 0.2 0.38 -0.7 to  1.1 
number of exacerbations in one year 0.0 0.46 -0.2 to  0.2 
fev1 % 0.0 0.09 0 to  0 
CAT summary score at T1 0.0 0.00 0 to  0.1 
Follow-up time (days) 0.0 0.01 0 to  0 
 113 
Secondary outcomes 114 
In GOLD C and D patients (n=67; 31%), no significant between-group difference 115 
appeared in the outcomes: integration of other healthcare providers, referral to 116 
pulmonary rehabilitation, or delivery of exacerbation action plans (Figure 2). 117 
After one year, the mean CAT summary score decreased from 10.7 to 9.5 (-1.2) 118 
in the intervention group and increased from 12.8 to 13.9 (+1.1) in the control group. 119 
Linear regression model adjusting for baseline disparities showed an estimated 120 
difference in change of -1,1 (95% CI = -3.3 to +1.1, p=0.32) in the intervention group. 121 
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Additional analyses 122 
Regarding intervention effects on individual key elements of COPD care, we 123 
identified different patterns. Implementation of certain key elements primarily 124 
increased in the intervention group (i.e. smoking cessation intervention, inhalation 125 
technique, patient education), while in other key elements between-group differences 126 
were primarily due to an attrition in the control group (i.e. smoking cessation advice, 127 
physical activity assessment and advice). Figure 3 illustrates net differences of 128 
implementation rates between T0 and T1 per studied group. 129 
The intervention effect on the primary outcome was stable and remained 130 
relevant in all sensitivity analyses: Multiple imputation method (imputed datasets 131 
n=5): between-group difference of +1.6 (95% CI +0.8 to +2.4); last observation 132 
carried forward method: +2.3 (95% CI +1.5 to +3.1), imputation of control group 133 
average: +2.0 (95% CI +1.3 to +2.8). 134 
To further explore the adoption of the intervention, we asked the GPs in the 135 
intervention group how they implemented the COPD care bundle in the T1 136 
questionnaire. In 47 (69%) patients, the GPs used the care bundle as the intended 137 
checklist to complete, but in 9 (13%) as a recall list only and in 12 (18%) the care 138 
bundle was not used at all. To further explore the intervention’s effects on health 139 
service utilisation, we assessed the 1-year frequency of planned and emergency 140 
COPD-driven practice visits as well as emergency department stays and 141 
hospitalisations at T1. A significant between-group difference appeared in the median 142 
number of planned practice visits: intervention group median = 3 (IQR 0 to 4) versus 143 
control group median = 1 (IQR 0 to 3; p=0.04) but not within the other modes of 144 
health service utilisation. 145 
  146 
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Discussion 147 
This cluster-randomised trial showed that a multifaceted intervention introducing 148 
a COPD care bundle to general practice teams increased the implementation rates of 149 
key elements of care compared to usual care based on patient self-report and 150 
previous 12-months recall. The between-group difference in implemented key 151 
elements of care was composed of an almost equal net increase in the intervention 152 
group and net decrease in the control group. The intervention therefore increased 153 
implementation rates of some key elements but also prevented the otherwise 154 
occurring attrition of others. More than two thirds of the patients were in early disease 155 
stages, significant intervention effects on disease-specific quality of life (CAT score) 156 
were not observed after one year.  157 
Care bundles are effective on relevant outcomes such as disease progression, 158 
quality of life or exacerbation rates in hospital based COPD care.[28] In our study, we 159 
detected significantly improved implementation of key elements recommended by 160 
guidelines and based on robust evidence.[15–25, 27] We were unable to detect a 161 
direct impact on quality of life. However, owing to early disease stages and the slowly 162 
progressing natural course of the disease, a longer surveillance period may be 163 
required to demonstrate effects on patient outcomes. Yet, particularly in early disease 164 
stages of COPD, interventions retain the greatest potential for effects and should 165 
therefore be cornerstone of care.[14, 34] In this context, it is noteworthy that we 166 
found the largest effects of our intervention for measures with strong evidence for 167 
improving prognosis including smoking cessation interventions, physical activity 168 
promotion, patient education and influenza vaccination. 169 
Complexity of care is associated with variation of care and integrated 170 
standardised pathways of care are advocated to improve quality and outcomes.[35] 171 
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Integration of care brings potential benefits to COPD patients and initiatives aim at 172 
fostering integrated care approaches in disease management for COPD.[27, 36] 173 
Integrated care is, however, an umbrella term for heterogeneous components of  174 
care organisation and not an unambiguously defined one-size-fits-all model.[37] 175 
Interestingly, the recent and so far largest trial testing integrated care for COPD by 176 
Kruis et. al. found no relevant effects on patient outcomes. This does not question 177 
integrated care in general but it illustrates that little is known about the effect of the 178 
individual components aligning under the term.[38] In this study, we promoted 179 
horizontal integration: redesigning COPD workflows handled by GPs and practice 180 
assistants and implementing a care bundle as a pragmatic, flexible and collaborative 181 
disease management aid. The significant increase of planned consultations in the 182 
intervention group can be interpreted as redesign towards more proactive care 183 
culture in the targeted practices.[39] 184 
We regard this study as a first and promising COPD care bundle 185 
implementation trial in general practice. However, subsequent research in the field is 186 
needed to better understand the potential of this approach. A direct integration of the 187 
care bundle in electronic medical records may increase its adoption by physicians, 188 
and further contribute to closing the gap in general practice health service delivery for 189 
COPD patients. Furthermore, relevant outcomes should be directly measured but 190 
longer surveillance periods should are required to enable this. The number of 191 
patients withdrawing from the study may be related to dissatisfaction with intensified 192 
healthcare delivery, possibly mediated by increasing costs and time expenditures. In 193 
Switzerland, only healthcare costs exceeding a patient-dependent minimum are 194 
reimbursed by statutory health insurance, therefore increased financial expenditures 195 
may have indeed contributed to dissatisfaction of a minority of patients. This effect 196 
may strongly vary according to financial coverage in different countries. The patient 197 
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experience of the intervention should be examined and the costs associated with any 198 
benefits gained should be considered before conclusions about net benefits of 199 
intensified disease-management can be drawn.  200 
 201 
Strengths and limitations of the study 202 
Some strengths and limitations must be mentioned: To our knowledge, this is 203 
the first report of a COPD care bundle implementation in general practice with a 204 
cluster randomised design. So far in this context the only available evidence was 205 
derived from hospital care or from general practice studies with different disease 206 
management interventions.[28–30] Another strength lies in the outcome assessment 207 
at the patient side: patient-recalled processes of care presumably reflect the 208 
successfully delivered elements of care better than the non-recalled ones. On the 209 
other hand, this implies the limitation that the trial presumably underestimates the 210 
actually delivered elements of care. This potential recall bias, however, does not 211 
invalidate the between group difference we detected. The trial’s open label design is 212 
clearly a limitation to the study. In the control group, GPs might have felt discouraged 213 
knowing about their allocation to the usual care group, biasing the between group 214 
difference in favour to the intervention group. Also, there is a risk for contamination 215 
bias because half of the patients were treated in group practices where GPs from 216 
both study arms were collocated. Contamination, however, would have biased our 217 
results towards zero and therefore rather strengthens our positive findings. The 218 
significantly higher drop-out rate in the intervention group is another important 219 
concern: even if reasons for drop-out were similar it is still possible that a subgroup of 220 
patients felt uncomfortable with intensified healthcare provided in the intervention 221 
group leading to undesirable self-deprivation from medical care. Lastly, despite 222 
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randomisation, we found a small but statistically significant difference in disease 223 
severity variables between the study groups with the intervention group being less 224 
severely affected by COPD. We believe, however, that the influence on disease 225 
management originating from this difference would have most likely resulted in 226 
intensified treatment in the more severely ill control group – again strengthening the 227 
trial’s positive finding. Ultimately, we must keep in mind that we attribute the study 228 
effects to a multifaceted and therefore “impure” intervention. Besides the care bundle 229 
or the team approach other factors delivered to the intervention group during the 230 
workshops (mainly knowledge about the key elements of COPD care) may have 231 
been important active components in the trial. 232 
 233 
Conclusions 234 
A disease management intervention for general practice care teams introducing 235 
a COPD care bundle increased the adherence to recommended key elements of 236 
care. Subsequent beneficial effects on relevant patient outcomes are plausible but 237 
may require years until they become apparent given the insidious disease 238 
progression and the early disease stages of COPD patients in general practice.  239 
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